Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2241-2255.e4

  Chandar, Apoorva Krishna ^a,b   Devanna, Swapna ^c   Lu, Chang ^a   Singh, Siddharth ^c   Greer, Katarina ^a,b   Chak, Amitabh ^a,b   Iyer, Prasad G ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Adipokines; Barrett's Esophagus; Leptin; Meta analysis; Systematic Review

Indexed keywords

ADIPOCYTOKINE; INSULIN; LEPTIN;

BARRETT ESOPHAGUS; CLINICAL EVALUATION; COLONOSCOPY; DISEASE ASSOCIATION; GASTROESOPHAGEAL REFLUX; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX RATIO; SYSTEMATIC REVIEW; BLOOD; CHEMISTRY; META ANALYSIS; SERUM;

ADIPOKINES; BARRETT ESOPHAGUS; HUMANS; INSULIN; RISK ASSESSMENT; SERUM;

EID: 84947424538     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.041     Document Type: Review

References (51)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Thrift A.P., Whiteman D.C. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012, 23:3155-3162.
3. Shaheen N., Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002, 287:1972-1981.
4. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143:199-211.
5. Singh S., Sharma A.N., Murad M.H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1399-1412 e7.
6. Hoyo C., Cook M.B., Kamangar F., et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012, 41:1706-1718.
7. Ayazi S., Hagen J.A., Chan L.S., et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. J Gastrointest Surg 2009, 13:1440-1447.
8. Pandolfino J.E., El-Serag H.B., Zhang Q., et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006, 130:639-649.
9. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
10. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
11. Coppola A., Marfella R., Coppola L., et al. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int J Cardiol 2009, 134:414-416.
12. Wolf A.M., Wolf D., Rumpold H., et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004, 323:630-635.
13. Brakenhielm E., Veitonmaki N., Cao R., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004, 101:2476-2481.
14. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
15. Havel P.J., Kasim-Karakas S., Dubuc G.R., et al. Gender differences in plasma leptin concentrations. Nat Med 1996, 2:949-950.
16. Sierra-Honigmann M.R., Nath A.K., Murakami C., et al. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686.
17. Ogunwobi O., Mutungi G., Beales I.L. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006, 147:4505-4516.
18. Beales I.L., Ogunwobi O.O. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007, 274:60-68.
19. Ogunwobi O.O., Beales I.L. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008, 285:43-50.
20. Schwartz M.W., Porte D. Diabetes, obesity, and the brain. Science 2005, 307:375-379.
21. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 2006, 17:305-323.
22. Greer K.B., Kresak A., Bednarchik B., et al. Insulin/insulin-like growth factor-1 pathway in Barrett's carcinogenesis. Clin Transl Gastroenterol 2013, 4:e31.
23. Silha J.V., Krsek M., Skrha J.V., et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335.
24. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
25. Yadav A., Kataria M.A., Saini V., et al. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013, 417:80-84.
26. Almers L.M., Graham J.E., Havel P.J., et al. Adiponectin may modify the risk of Barrett's esophagus in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2015, 13:2256-2264.
27. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12:229-238 e3.
28. Greer K.B., Falk G.W., Bednarchik B., et al. Associations of serum adiponectin and leptin with Barrett's esophagus. Clin Gastroenterol Hepatol 2015, 13:2265-2272.
29. Greer K.B., Thompson C.L., Brenner L., et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut 2012, 61:665-672.
30. Kendall B.J., Macdonald G.A., Hayward N.K., et al. Leptin and the risk of Barrett's oesophagus. Gut 2008, 57:448-454.
31. Rubenstein J.H., Dahlkemper A., Kao J.Y., et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103:1358-1364.
32. Rubenstein J.H., Kao J.Y., Madanick R.D., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.
33. Rubenstein J.H., Morgenstern H., McConell D., et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology 2013, 145:1237-1244. e1-5.
34. Thompson O.M., Beresford S.A., Kirk E.A., et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010, 18:2204-2211.
35. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.
37. El-Serag H.B., Sweet S., Winchester C.C., et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014, 63:871-880.
38. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. [cited 2014 June 27]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
39. Review Manager (RevMan) [Computer program]. Version 5.3 2014, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
40. Mokrowiecka A., Daniel P., Jasinska A., et al. Serum adiponectin, resistin, leptin concentration and central adiposity parameters in Barrett's esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD. Hepatogastroenterology 2012, 59:2395-2399.
41. Healy L.A., Ryan A.M., Pidgeon G., et al. Lack of differential pattern in central adiposity and metabolic syndrome in Barrett's esophagus and gastroesophageal reflux disease. Dis Esophagus 2010, 23:386-391.
42. Francois F., Roper J., Goodman A.J., et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008, 57:16-24.
43. Garofalo C., Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207:12-22.
44. Konturek P.C., Brzozowski T., Sulekova Z., et al. Role of leptin in ulcer healing. Eur J Pharmacol 2001, 414:87-97.
45. Suzuki S., Wilson-Kubalek E.M., Wert D., et al. The oligomeric structure of high molecular weight adiponectin. FEBS Lett 2007, 581:809-814.
46. Schober F., Neumeier M., Weigert J., et al. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochem Biophys Res Commun 2007, 361:968-973.
47. Clemons N.J., Phillips W.A., Lord R.V. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther 2013, 14:782-795.
48. Duggan C., Onstad L., Hardikar S., et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013, 11:934-943.
49. Iyer P.G., Borah B.J., Heien H.C., et al. Association of Barrett's esophagus with type II diabetes mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol 2013, 11:1108-1114 e5.
50. Kern P.A., Ranganathan S., Li C., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-751.
51. Cook M.B., Shaheen N.J., Anderson L.A., et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012, 142:744-753.